AETERNA ZENTARIS INC
Latest Quote @ Tue May 5 19:54:06 (15 min delayed)
Last Day's Data
AEterna Zentaris, Inc., a biopharmaceutical company, engages in the discovery, development, and marketing of oncology and endocrine therapy focused drugs. Its product line leverages five different therapeutic approaches such as: luteinizing hormone releasing hormone (LHRH) antagonists, signal transduction inhibitors, cytotoxic conjugates and cytotoxics, tubulin inhibitors/vascular targeting agents, and growth hormone modulators. The company markets cetrorelix for in vitro fertilization and Impavido for black fever and parasitic skin diseases. Its other products, which are in various stages of clinical development include D-63153, a linear decapeptide sequence; Teverelix; Perifosine, an alkylphosphocholine compound; Erucylphosphocholine, an analog of perifosine, for intravenous administration; Miltefosine; PI3K Inhibitors; Lobaplatin, a platinum derivative; Disorazol E for the treatment of cancer; Neovastat, an oral antiangiogenic product; RC-3095 a hormone-like peptide; GH-RH Antagonists; and Ghrelin Receptor Antagonists. The company, through Atrium Biotechnologies, Inc., develops and markets active ingredients, specialty fine chemicals, cosmetic, and nutritional products for the cosmetics, chemical, pharmaceutical, and nutritional industries. AEterna Zentaris has strategic alliances with Serono International S.A.; Solvay Pharmaceuticals Bv.; Shionogi &amp; Co., Ltd.; Nippon Kayaku Co., Ltd.; German Remedies; Spectrum Pharmaceuticals, Inc.; Ardana Bioscience, Ltd.; Grupo Ferrer; LG Life Sciences; Mayne Pharma; and Ardana Bioscience, Ltd. The company was founded in 1990. It was formerly known as 171162 Canada, Inc. and changed its name to Les Laboratoires Aeterna, Inc. in 1991. Further, the company changed its name to AEterna Laboratories, Inc. in 1997 and to AEterna Zentaris, Inc. in 2004. AEterna Zentaris is headquartered in Quebec City, Canada.